Azenta, Inc. AZTA
We are a leading global provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. We entered the life sciences market in 2011, leveraging our in-house precision automation and cryogenics capabilities that we were then applying in the semiconductor manufacturing market. This led us to develop and provide solutions for automated ultra-cold storage. Since then, we have expanded our life sciences offerings through internal investments and through a series of acquisitions. We support our customers from research and clinical development to commercialization with our sample management and automated storage systems, as well as genomic services expertise to help our customers bring impactful therapies to market faster. We understand the importance of sample integrity and offer a broad portfolio of products and services supporting customers at every stage of the life cycle of samples, including procurement, automated storage systems, genomic services and a multitude of sample consumables, informatics and data software, along with sample repository services. Our expertise, global footprint, and leadership positions enable us to be a trusted global partner to pharmaceutical, biotechnology and life sciences research institutions. In total, we employ approximately 3,000 full-time employees, part-time employees and contingent workers worldwide as of September 30, 2025 and have sales in approximately 95 countries. We are headquartered in Burlington, Massachusetts and have operations in North America, Asia and Europe.
Valuation FY2025 figures against the last close
Where the revenue comes from as reported in the latest 10-K
Revenue by geography
- United States
- Europe
- China
- United Kingdom
- Asia Pacific
- Other
| Region | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| United States | $365.0M | $365.1M | $351.4M |
| Europe | $107.4M | $95.2M | $87.2M |
| China | $58.3M | $58.2M | $52.1M |
| United Kingdom | $35.4M | $27.2M | $26.7M |
| Asia Pacific | $23.3M | $21.3M | $25.6M |
| Other | $4.4M | $6.5M | $8.5M |
As the company reported it, from the “Note 18 - Segment and Geographic Information - Schedule of Revenue by Geographic Area (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $593.8M | $573.4M | $551.5M | $555.5M | $513.7M | $388.5M | $334.2M | $631.6M | $527.5M | $434.0M |
| Cost of revenue | $323.5M | $318.8M | $312.3M | $299.9M | $269.9M | $216.4M | $199.6M | $385.5M | $328.6M | $277.3M |
| Gross profit | $270.3M | $254.6M | $239.2M | $255.6M | $243.8M | $172.1M | $134.6M | $246.1M | $198.9M | $156.7M |
| R&D | $30.4M | $31.5M | $32.1M | $27.5M | $22.4M | $17.8M | $17.3M | $46.9M | $39.9M | $44.2M |
| SG&A | $261.6M | $263.0M | $263.7M | $251.5M | $252.1M | $190.3M | $163.3M | $167.0M | $141.5M | $119.3M |
| Total operating expenses | $297.1M | $305.9M | $300.5M | $280.3M | $274.9M | $208.7M | $182.0M | $214.7M | $184.6M | $173.7M |
| Operating income | -$26.8M | -$51.3M | -$61.2M | -$24.7M | -$31.1M | -$36.6M | -$47.4M | $31.4M | $14.3M | -$17.1M |
| Interest expense | — | — | — | $4.6M | $2.0M | $2.9M | $22.2M | $9.5M | $408.0K | $157.0K |
| Pre-tax income | -$7.1M | -$19.1M | -$20.0M | -$9.9M | -$49.0M | -$40.3M | -$84.0M | $20.5M | $14.5M | -$18.1M |
| Income tax | $31.6M | $5.2M | $12.0M | $1.4M | $20.1M | $13.9M | $22.8M | $47.3M | $3.4M | $66.2M |
| Net income | -$55.8M | -$164.9M | -$14.6M | $2.13B | $110.7M | $64.9M | $437.4M | $116.6M | $62.6M | -$69.5M |
| EPS, basic | -1.22 | -3.10 | -0.22 | 28.48 | 1.49 | 0.88 | 6.08 | 1.65 | 0.90 | -1.01 |
| EPS, diluted | -1.22 | -3.10 | -0.22 | 28.48 | 1.49 | 0.88 | 6.04 | 1.64 | 0.89 | -1.01 |
| Shares, diluted (wtd. avg.) | 45.9M | 53.2M | 66.3M | 74.9M | 74.5M | 73.8M | 72.4M | 70.9M | 70.5M | 68.5M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $279.8M | $280.0M | $649.5M | $658.3M | $227.4M | $250.6M | $256.6M | $197.7M | $101.6M | $85.1M |
| Short-term investments | $61.1M | $151.2M | $338.9M | $911.8M | $81.0K | $51.0K | $34.1M | $46.3M | — | — |
| Receivables | $142.2M | $154.2M | $156.5M | $163.8M | $119.9M | $94.8M | $165.6M | $125.2M | $93.5M | $106.4M |
| Inventory | $80.8M | $71.3M | $128.2M | $85.5M | $60.4M | $37.1M | $99.4M | $97.0M | $73.4M | $92.6M |
| Total current assets | $678.3M | $833.0M | $1.42B | $2.46B | $777.4M | $649.5M | $647.1M | $564.1M | $351.8M | $299.3M |
| Property, plant and equipment | — | — | — | — | — | — | $100.7M | $60.0M | $57.0M | $54.9M |
| Goodwill | $702.4M | $691.4M | $675.4M | $513.6M | $469.4M | $453.2M | $440.8M | $255.9M | $207.2M | $175.7M |
| Other intangibles | $101.8M | $125.0M | $294.3M | $178.4M | $186.5M | $212.3M | $251.2M | $100.0M | $83.5M | $81.8M |
| Total assets | $2.02B | $2.10B | $2.89B | $3.72B | $1.82B | $1.56B | $1.52B | $1.10B | $766.6M | $685.9M |
| Accounts payable | $38.3M | $33.3M | $35.8M | $38.7M | $42.4M | $25.7M | $58.9M | $44.7M | $49.1M | $41.1M |
| Short-term debt | — | — | — | — | — | $827.0K | $829.0K | $2.0M | — | — |
| Total current liabilities | $246.2M | $206.1M | $210.9M | $230.5M | $345.1M | $211.1M | $272.3M | $164.6M | $146.8M | $119.8M |
| Long-term debt | — | — | — | — | $49.7M | $49.6M | $50.3M | $194.1M | — | — |
| Total liabilities | $346.0M | $332.4M | $351.2M | $352.7M | $494.2M | $345.7M | $377.0M | $377.4M | $159.0M | $132.2M |
| Retained earnings | $1.37B | $1.48B | $1.64B | $1.66B | -$470.1M | -$551.1M | -$586.4M | -$994.1M | -$1.08B | -$1.12B |
| Total equity | $1.67B | $1.77B | $2.53B | $3.36B | $1.33B | $1.21B | $1.14B | $717.8M | $607.6M | $553.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $72.2M | $49.7M | $5.8M | -$466.0M | $149.9M | $37.9M | $90.9M | $74.0M | $96.2M | $39.5M |
| Depreciation and amortisation | $32.0M | $29.7M | $29.3M | $21.9M | $19.5M | $18.7M | $14.0M | $12.5M | $10.1M | $12.2M |
| Stock-based compensation | $20.9M | $14.5M | $9.4M | $10.7M | $27.5M | $16.3M | $20.1M | $19.8M | $17.3M | $11.7M |
| Capital expenditure | $33.9M | $37.4M | $39.4M | $73.4M | $52.8M | $39.9M | $23.9M | $12.8M | $12.7M | $12.8M |
| Investing cash flow | -$90.5M | $224.7M | $431.4M | $1.47B | -$146.3M | -$22.7M | $211.3M | -$148.5M | -$54.2M | -$10.9M |
| Financing cash flow | -$9.6M | -$659.2M | -$840.5M | -$62.8M | -$25.9M | -$27.0M | -$191.2M | $170.3M | -$25.9M | -$26.0M |
| Dividends paid | — | $0 | $0 | $7.5M | $29.7M | $29.5M | $28.9M | $28.3M | $27.9M | $27.5M |
| Buybacks | $0 | $661.7M | $838.5M | $0 | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001437749-25-036931.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $434.0M | $527.5M | $631.6M | $334.2M | $388.5M | $513.7M | $555.5M | $551.5M | $573.4M | $593.8M |
| Gross profit | $156.7M | $198.9M | $246.1M | $134.6M | $172.1M | $243.8M | $255.6M | $239.2M | $254.6M | $270.3M |
| Net income | -$69.5M | $62.6M | $116.6M | $437.4M | $64.9M | $110.7M | $2.13B | -$14.6M | -$164.9M | -$55.8M |
Recent filings and events
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Item 7.01
- Officer or director change Item 5.02
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
- Regulation FD disclosure Item 7.01
- Results announced Item 2.02
- Officer or director change Item 5.02
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3559
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LRCX | LAM RESEARCH CORP | $287.93B | 39.9x | 26.0% |
| ACMR | ACM Research, Inc. | $3.43B | 36.9x | 15.2% |
| ACLS | AXCELIS TECHNOLOGIES INC | $3.29B | 28.0x | -17.6% |
| VECO | VEECO INSTRUMENTS INC | $2.57B | 71.3x | -7.4% |
| CRCT | Cricut, Inc. | $1.31B | 17.9x | -0.5% |
| ERII | Energy Recovery, Inc. | $341.0M | 15.9x | -6.9% |
| ASYS | AMTECH SYSTEMS INC | $217.5M | — | -21.6% |
| VELO | Velo3D, Inc. | $213.5M | — | 12.1% |